SuperTruth Pledges No Profit From Kids, Rewriting Tech Philanthropy

PHILADELPHIA, PA – May 01, 2026 – In a move that challenges the established norms of corporate social responsibility, healthcare data startup SuperTruth has launched its business with a radical commitment: it will never profit from children. The company today announced the creation of Sean's Friends, a donor-advised fund, and a binding pledge to direct all future revenue earned from pediatric data or children's hospitals directly into the fund.

This is not a philanthropic arm created after years of profitability, but a core component of the company's operating model from day one. Inspired by the rare disease diagnosis of co-founder Bobby Hill's son, Sean, the initiative aims to create a new, direct pipeline of support for pediatric research, hospitals, and families crushed by the financial weight of a child's illness.

A Founding Tenet, Not an Afterthought

SuperTruth, which is building a verification system to score the trustworthiness of data used in medical AI, is flipping the script on corporate giving. While many tech giants and established corporations create foundations or charitable arms as part of their governance or public relations strategy, SuperTruth has embedded philanthropy into its foundational DNA.

"This is a founding tenet of the company, not a future arm," said Bobby Hill, who celebrated his 35th birthday with the announcement. "Most healthcare companies wait until they have the right amount of extra profit to spin up a philanthropic arm that checks a governance box for pharma. We are doing this on day one, before the money is in the door, because the order matters. Giving is the tenet. Profit follows the tenet, not the other way around."

The fund, named Sean's Friends, is a donor-advised fund (DAF) administered through Fidelity Charitable, a 501(c)(3) public charity. This structure allows donors to receive an immediate tax deduction, while the funds can be invested to grow tax-free before being granted to qualified non-profits. While DAFs have faced some criticism for a lack of mandated payout timelines, SuperTruth aims for transparency by making its commitment public and ensuring the fund's mechanics are traceable. Critically, the structure ensures that no money from the DAF can ever return to SuperTruth itself.

The company’s first grant has already been directed to the Children's Hospital of Philadelphia (CHOP), specifically to the NICU and pulmonary research teams who have cared for Hill's son, Sean.

The Personal Cost of Flawed Data

The mission of both SuperTruth and Sean's Friends is deeply rooted in personal loss and near-tragedy. The founders see flawed healthcare data not as a technical glitch, but as a systemic failure with a human toll.

"I made my father a promise in a hospital room. He died because a PET scan result disappeared into a system with no mechanism to surface it," said Jason Snyder, SuperTruth's co-founder. "Bobby nearly lost Sean to the same failure: a rare diagnosis buried in data that no physician could connect or trust. We built SuperTruth because unverified data in healthcare is not a technical problem. It has a body count."

That body count extends to the financial and emotional devastation faced by families. The idea for Sean's Friends was conceived in the hospital room where Hill's son was diagnosed. Hill recalls a conversation that has haunted him since: "The head of research told us in our diagnosis meeting that most of the dollars funding rare disease research come from parents like us. Parents who are already drowning," he said. "The system asks the families with the sickest kids to also be the ones writing the checks that fund the cure. That is not sustainable, and it is not right."

This experience shaped the fund's purpose: to serve as a resource for families needing help to bring a child home, for researchers struggling for grants, and for donors who want to make a direct impact. "Sean has had every advantage a child in his situation could have," Hill stated. "Sean's Friends is about closing that gap."

Bridging a Critical Funding Chasm

The launch of Sean's Friends arrives at a critical moment for pediatric medicine. The funding landscape for rare diseases—which affect one in nine Americans and disproportionately impact children—is fraught with challenges. Federal funding from sources like the National Institutes of Health (NIH), while substantial, is tightening and cannot cover every need. Studies have shown that diseases with a high burden, like neonatal disorders, are often under-prioritized by both government and industry funding.

This has left a significant gap that philanthropy is increasingly trying to fill. However, large-scale philanthropic efforts can sometimes be slow to translate into bedside care. Hill pointed to the stark contrast in capital allocation, noting massive investments in AI models while children's hospitals struggle to staff researchers. "The asymmetry is the story," Hill said. "Sean's Friends puts dollars and tools directly into the hands of the people taking care of these kids, with no middleman, no building campaign, no headline donor wing."

By pledging all pediatric-related revenue, SuperTruth is creating a perpetually replenishing source of funds dedicated solely to this cause. The model is open by design, intended to support any qualified pediatric research organization or family in need, not just CHOP. Potential beneficiaries include renowned institutions like Boston Children's Hospital and St. Jude Children's Research Hospital, as well as the numerous rare disease advocacy groups that form the backbone of patient support.

Hill emphasized that the model is replicable. "If you want to fund research at the hospital that saved your child, this is a vehicle you can use," he said. "We will help you set it up. The point is not that this is our fund. The point is that this is a working answer to a problem nobody is solving fast enough."